PCNU用于难治性晚期乳腺癌的II期试验。

Phase II trail of PCNU in refractory advanced breast cancer.

作者信息

Kavanagh J J, Yap H Y, Blumenschein G R, Stewart D, Bodey G P

出版信息

Am J Clin Oncol. 1982 Jun;5(3):249-51. doi: 10.1097/00000421-198206000-00002.

DOI:10.1097/00000421-198206000-00002

Abstract

An evaluation of PCNU was carried out in 28 patients with extensively treated refractory breast cancer. The starting dose was 60 mg/m2 in 13 patients and 90 mg/m2 in 15 patients given intravenously every 6 weeks. The major side effect was myelosuppression, manifested mainly as thrombocytopenia. Nonhematologic side effects were minimal, consisting mainly of transient nausea. One mixed response was seen. Four patients had stable disease. PCNU demonstrated limited activity in advanced breast cancer and was not effective in the treatment of central nervous system metastases.

摘要

对28例接受过广泛治疗的难治性乳腺癌患者进行了氯乙基亚硝脲（PCNU）评估。起始剂量为60mg/m²，共13例患者；15例患者起始剂量为90mg/m²，均每6周静脉给药一次。主要副作用为骨髓抑制，主要表现为血小板减少。非血液学副作用轻微，主要为短暂性恶心。观察到1例混合反应。4例患者病情稳定。PCNU在晚期乳腺癌中显示出有限的活性，对中枢神经系统转移瘤治疗无效。